The forthcoming SpaceX initial public offering presents an unusual opportunity to examine an underexplored corner of insurance law. Under Texas law, which governs as the jurisdiction of Elon Musk’s domicile, every investor who purchases shares in the SpaceX IPO may plausibly be characterized as holding a cognizable insurable interest in Musk’s continued life. The argument is novel in its application, but it rests on foundations that are entirely conventional under Texas doctrine once the IPO’s own disclosures are taken seriously.
The Texas Framework
Texas has long been among the most permissive jurisdictions in the country with respect to insurable interest.[1] The Texas Insurance Code and the case law interpreting it recognize that an insurable interest in the life of another may arise from a legitimate economic relationship in which the interest-holder would suffer a quantifiable financial loss from the insured’s premature death. No blood relationship, no privity and no formal contractual tie to the insured are required.[2] Courts and treatises in this area consistently articulate the standard as whether the putative interest-holder “has more to lose than to gain” from the insured’s death,[3]a formulation that captures both the equitable and the functional core of the doctrine while neatly excluding the wagering contracts that insurable interest rules were originally designed to prohibit.
Courts applying Texas law have extended this standard to lenders, creditors, minority equity holders, business partners, and parties to key-man insurance arrangements in closely held companies.[4] Nothing in the statutory text or the case law restricts the legitimate economic relationship concept to any particular corporate structure, ownership threshold, or mode of holding equity.
The SpaceX Disclosure as the Legal Foundation
The SpaceX IPO materials are, quite remarkably, the strongest single argument for recognizing investor insurable interest in Musk. SpaceX’s public filings expressly characterize Musk as the singular driving force behind the company’s growth, innovation, and strategic direction. Independent market analysts have been equally candid: one widely cited commentator has stated that SpaceX’s valuation, currently set at $1.77 trillion, is “completely dependent on the degree to which people believe in Elon Musk”[5] and is not justified solely by current business performance. Starlink, SpaceX’s primary revenue engine, cannot alone support the IPO’s valuation thesis; the premium above that baseline is, by the market’s own admission, a function of Musk’s unique combination of engineering vision, capital-raising capacity, and regulatory influence.
When an issuer tells the public market that enterprise value is a function of a single human being and then sells that proposition at scale into retail channels, each purchaser has, as a matter of economic substance, acquired a direct and quantifiable exposure to that individual’s continued survival and productivity. The “delta” between SpaceX with Musk and SpaceX without Musk is precisely the potential financial loss sufficient to warrant compensation that the Texas-oriented authority identifies as the hallmark of insurable interest.
The Inversion of the Classic Key-Man Paradigm
Traditional key-man life insurance analysis begins with a corporation purchasing coverage on a founder or executive whose loss would impair corporate value. SpaceX has conspicuously elected not to maintain formal key-person coverage on Musk despite its acknowledged dependence on him. Rather than concentrating that life-risk in a single corporate policy, the IPO effectively distributes it across the entire public float. Thus, each share functions as a micro-allocation of Musk-dependent risk, held by an investor who, in the most direct economic sense, is long on his survival.
A reasonable court applying Texas’s legitimate economic relationship standard should find no principled basis for distinguishing that position from the classic key-man fact pattern. SpaceX itself has an insurable interest in Musk under any reasonable reading of Texas law; the investors who have purchased the equity that embeds and monetizes that dependence occupy the same economic position in disaggregated form. Insurable interest doctrine is animated by a public-policy concern that coverage not function as a naked wager on death. That concern is entirely absent here: no one is buying SpaceX stock in the hope that Musk dies. Each investor’s exposure to his mortality arises from a legitimate investment, not a manufactured speculation, and the law recognizes precisely that distinction.
The Opportunity — and Its Limits?
The recognition of investor insurable interest raises a natural follow-on question: could the “delta” be insured? Analysts broadly agree that Starlink’s stand-alone value accounts for only a fraction of SpaceX’s IPO price; the remainder, conservatively in the range of $1 trillion or more, represents the perceived value of Musk’s continued vision, execution, and political influence. To put that figure in human terms: total US life insurance in force stood at $62.42 trillion at year-end 2024,[6] covering roughly 134 million individual life insurance policies,[7] at an average face amount of approximately $206,000 each. A death benefit sized to cover the entire Musk-attributable valuation premium would be the actuarial equivalent of writing a policy on roughly 5 million average American lives at once.
Sizing the risk to correspond to the expected IPO raise of approximately $75 to $80 billion brings the market bet on Musk’s life to a more comprehensible figure of around $40 billion. Still, no single insurer could touch it. No syndicate of reinsurers would likely want to absorb it. The SpaceX IPO asks the public to assume a concentration of mortality risk on a scale that the entire insurance industry — whose very purpose is to price and distribute exactly this kind of exposure — has never been asked to contemplate, let alone cover. Investors in SpaceX would do well to understand what they are actually buying: not just a rocket company, but a very large, and, perhaps until now, entirely unhedgeable bet on one man staying alive.
Lucy Hafitz, a summer associate in Katten’s New York office, contributed to this advisory.
[1] Tex. Ins. Code §§ 1103.003, 1103.004, 1103.054, 1103.056.
[2] Drane v. Jefferson Standard Life Ins. Co., 161 S.W.2d 1057, 1058–59 (Tex. 1942); see also Allen v. United of Omaha Life Ins. Co., 236 S.W.3d 315, 323 (Tex. App.—Fort Worth 2007, pet. denied) (recognizing that under Texas law, the insured’s designation of a beneficiary in compliance with Tex. Ins. Code §§ 1103.054, 1103.056 is sufficient to confer an insurable interest).
[3] Howard M. Zaritsky & Stephan R. Leimberg, Tax Planning with Life Insurance § 1.15 (2d ed. 2012); Warnock v. Davis, 104 U.S. 775, 779 (1881).
[4] Drane, 161 S.W.2d at 1058; Smith v. Schoellkopf, 68 S.W.2d 346, 350 (Tex. Civ. App. 1934); Dunn v. Second Nat’l Bank, 113 S.W.2d 165, 169–70 (Tex. Comm’n App. 1938); Tex. Ins. Code §§ 1103.003 (insurable interest of partnerships and members), 1103.004 (insurable interest of employers and corporations in officers and stockholders) (recodifying without substantive change former Tex. Ins. Code art. 10.12); Mayo v. Hartford Life Ins. Co., 354 F.3d 400 (5th Cir. 2004).
